Contributions
Abstract: S138
Type: Oral Presentation
Session title: Developments in AML therapy
Background
Olutasidenib, a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1), has exhibited favorable tolerability and clinical activity in high-risk acute myeloid leukemia (AML) patients (pts) in a phase 1 trial (Watts, Blood 2019).
Aims
Here, we present interim analysis results of a phase 2 trial (NCT02719574) in relapsed/refractory (R/R) mIDH1 AML pts receiving olutasidenib monotherapy 150 mg twice daily.
Methods
The efficacy evaluable (EE) set comprised mIDH1R132X pts whose first dose was ≥180 days before the data cut-off (18-JUN-20). The primary endpoint was CR + CRh (complete remission [CR] or CR with partial hematologic recovery [CRh] according to modified IWG 2003 criteria) rate. CRh was defined as bone marrow blasts <5%, absolute neutrophil count >0.5×109/L, and platelet count >50×109/L. Overall response rate (ORR) comprised CR + CRh + CR with incomplete recovery (CRi) + morphologic leukemia-free state (MLFS) + partial response (PR). Duration of treatment (DOT), duration of response (DOR), and overall survival (OS) were estimated using Kaplan-Meier methodology.
Results
This clinical trial met its pre-specified early enrollment-stopping criteria for efficacy. A total of 153 pts with R/R AML received olutasidenib; median DOT, 5.5 months (95% CI: 4.4–8.7). 43 pts (28%) remain on treatment and 110 pts (72%) discontinued, most commonly due to: disease progression (31%), AEs (14%), death (10%), and transplant (8%). For the EE set (123 pts), the median age was 71 y (range: 32‒87) with a median number of prior therapies of 2 (1‒7). The ORR was 46% with a median duration of ORR of 11.7 months. Notably, the CR + CRh rate was 33% including 30% of pts in CR. The median duration of CR + CRh was not reached (NR) but found to be 13.8 months based on a sensitivity analysis when HSCT or relapse was deemed end of response. Of responders who were transfusion-dependent at baseline, 56-day platelet transfusion independence (TI) and RBC TI were gained by 100% and 83%, respectively, of pts who achieved CR + CRh, and by 56% and 50% who did not. The median OS was 10.5 months. For patients with CR + CRh, the median OS was NR and the estimated 18‑month OS was 87%; the median OS for non-CR/CRh responders was 15.0 months (Figure). TEAEs in ≥25% of pts were: nausea (38%), constipation (25%), and leukocytosis (25%). Grade 3/4 all-causality AEs in >10% of pts were: febrile neutropenia (20%), anemia (19%), thrombocytopenia (16%), and neutropenia (13%). TEAEs of QTc prolongation (all grades) were reported in 13 pts (8.5%) with one grade 3 event in 1 pt (<1%). No events led to dose reduction or discontinuation. Hepatobiliary TEAEs associated with liver enzyme abnormalities (all grades) were reported in 32 pts (21%) with grade 3/4 events in 16 pts (10%)/3 pts (2%). Most pts (n=25) had no dose modification or continued after a rechallenge; 7 pts with grade 3/4 events discontinued treatment (4 pts after positive rechallenge). There were no Hy’s law cases. Investigator-assessed IDH1 differentiation syndrome (any grade) was observed in 21 pts (14%); most cases resolved with treatment interruption, dexamethasone, and/or supportive treatment; one case was fatal; 19 pts had concomitant leukocytosis.
Conclusion
Olutasidenib induced durable CRs in a subset of high-risk R/R mIDH1 AML pts. TI was achieved in all response groups, particularly in those achieving CR. Clinical benefit, as evidenced by DOR and OS, extended to pts who responded but didn’t achieve CR/CRh. A favorable tolerability profile was observed; additional analyses of safety and efficacy will be presented.
Keyword(s): Clinical trial, Complete remission, Refractory, Relapsed acute myeloid leukemia
Abstract: S138
Type: Oral Presentation
Session title: Developments in AML therapy
Background
Olutasidenib, a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1), has exhibited favorable tolerability and clinical activity in high-risk acute myeloid leukemia (AML) patients (pts) in a phase 1 trial (Watts, Blood 2019).
Aims
Here, we present interim analysis results of a phase 2 trial (NCT02719574) in relapsed/refractory (R/R) mIDH1 AML pts receiving olutasidenib monotherapy 150 mg twice daily.
Methods
The efficacy evaluable (EE) set comprised mIDH1R132X pts whose first dose was ≥180 days before the data cut-off (18-JUN-20). The primary endpoint was CR + CRh (complete remission [CR] or CR with partial hematologic recovery [CRh] according to modified IWG 2003 criteria) rate. CRh was defined as bone marrow blasts <5%, absolute neutrophil count >0.5×109/L, and platelet count >50×109/L. Overall response rate (ORR) comprised CR + CRh + CR with incomplete recovery (CRi) + morphologic leukemia-free state (MLFS) + partial response (PR). Duration of treatment (DOT), duration of response (DOR), and overall survival (OS) were estimated using Kaplan-Meier methodology.
Results
This clinical trial met its pre-specified early enrollment-stopping criteria for efficacy. A total of 153 pts with R/R AML received olutasidenib; median DOT, 5.5 months (95% CI: 4.4–8.7). 43 pts (28%) remain on treatment and 110 pts (72%) discontinued, most commonly due to: disease progression (31%), AEs (14%), death (10%), and transplant (8%). For the EE set (123 pts), the median age was 71 y (range: 32‒87) with a median number of prior therapies of 2 (1‒7). The ORR was 46% with a median duration of ORR of 11.7 months. Notably, the CR + CRh rate was 33% including 30% of pts in CR. The median duration of CR + CRh was not reached (NR) but found to be 13.8 months based on a sensitivity analysis when HSCT or relapse was deemed end of response. Of responders who were transfusion-dependent at baseline, 56-day platelet transfusion independence (TI) and RBC TI were gained by 100% and 83%, respectively, of pts who achieved CR + CRh, and by 56% and 50% who did not. The median OS was 10.5 months. For patients with CR + CRh, the median OS was NR and the estimated 18‑month OS was 87%; the median OS for non-CR/CRh responders was 15.0 months (Figure). TEAEs in ≥25% of pts were: nausea (38%), constipation (25%), and leukocytosis (25%). Grade 3/4 all-causality AEs in >10% of pts were: febrile neutropenia (20%), anemia (19%), thrombocytopenia (16%), and neutropenia (13%). TEAEs of QTc prolongation (all grades) were reported in 13 pts (8.5%) with one grade 3 event in 1 pt (<1%). No events led to dose reduction or discontinuation. Hepatobiliary TEAEs associated with liver enzyme abnormalities (all grades) were reported in 32 pts (21%) with grade 3/4 events in 16 pts (10%)/3 pts (2%). Most pts (n=25) had no dose modification or continued after a rechallenge; 7 pts with grade 3/4 events discontinued treatment (4 pts after positive rechallenge). There were no Hy’s law cases. Investigator-assessed IDH1 differentiation syndrome (any grade) was observed in 21 pts (14%); most cases resolved with treatment interruption, dexamethasone, and/or supportive treatment; one case was fatal; 19 pts had concomitant leukocytosis.
Conclusion
Olutasidenib induced durable CRs in a subset of high-risk R/R mIDH1 AML pts. TI was achieved in all response groups, particularly in those achieving CR. Clinical benefit, as evidenced by DOR and OS, extended to pts who responded but didn’t achieve CR/CRh. A favorable tolerability profile was observed; additional analyses of safety and efficacy will be presented.
Keyword(s): Clinical trial, Complete remission, Refractory, Relapsed acute myeloid leukemia